Taking these results together, we demonstrated that pro‐Adalimumab could regain its activity to neutralize TNFɑ without interference from anti‐Adalimumab Id Ab in the disease region, further reducing the RA progression. The gene discussed is TNF; the disease is rheumatoid arthritis.